ES2098229T3 - Compuestos de pirazolopiridina y procedimientos para su preparacion. - Google Patents

Compuestos de pirazolopiridina y procedimientos para su preparacion.

Info

Publication number
ES2098229T3
ES2098229T3 ES90101042T ES90101042T ES2098229T3 ES 2098229 T3 ES2098229 T3 ES 2098229T3 ES 90101042 T ES90101042 T ES 90101042T ES 90101042 T ES90101042 T ES 90101042T ES 2098229 T3 ES2098229 T3 ES 2098229T3
Authority
ES
Spain
Prior art keywords
pirazolopyridine
procedures
compounds
preparation
computable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90101042T
Other languages
English (en)
Spanish (es)
Inventor
Youichi Shiokawa
Atsushi Akahane
Hirohito Katayama
Takafumi Mitsunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2098229T3 publication Critical patent/ES2098229T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES90101042T 1989-01-23 1990-01-19 Compuestos de pirazolopiridina y procedimientos para su preparacion. Expired - Lifetime ES2098229T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898901423A GB8901423D0 (en) 1989-01-23 1989-01-23 Pyrazolopyridine compound and processes for preparation thereof

Publications (1)

Publication Number Publication Date
ES2098229T3 true ES2098229T3 (es) 1997-05-01

Family

ID=10650453

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90101042T Expired - Lifetime ES2098229T3 (es) 1989-01-23 1990-01-19 Compuestos de pirazolopiridina y procedimientos para su preparacion.

Country Status (23)

Country Link
US (1) US4985444A (enExample)
EP (1) EP0379979B1 (enExample)
JP (2) JPH0794454B2 (enExample)
KR (1) KR0159502B1 (enExample)
CN (1) CN1031570C (enExample)
AT (1) ATE150462T1 (enExample)
AU (1) AU628913B2 (enExample)
CA (1) CA2008263C (enExample)
DE (1) DE69030206T2 (enExample)
DK (1) DK0379979T3 (enExample)
ES (1) ES2098229T3 (enExample)
FI (1) FI96205C (enExample)
GB (1) GB8901423D0 (enExample)
GR (1) GR3023219T3 (enExample)
HU (2) HUT53368A (enExample)
IE (1) IE900161L (enExample)
IL (1) IL93050A (enExample)
NO (1) NO176356C (enExample)
PH (1) PH30968A (enExample)
PT (1) PT92935B (enExample)
RU (1) RU2007403C1 (enExample)
UA (1) UA43821C2 (enExample)
ZA (1) ZA90200B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
EP0644762B1 (en) * 1992-06-10 1997-12-17 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds for the treatment of anemia
AU7546794A (en) * 1993-09-06 1995-03-27 Kyowa Hakko Kogyo Co. Ltd. Depression remedy
HUT76280A (en) * 1993-12-29 1997-07-28 Fujisawa Pharmaceutical Co Pyrazolopyridine derivatives, pharmaceutical compositions containing them, process for proiducing them and their use
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
RU2172742C2 (ru) * 1995-12-28 2001-08-27 Пфайзер Инк. Стимуляторы секреции гормона роста
US6214843B1 (en) * 1996-04-25 2001-04-10 Fujitsawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
ES2187814T3 (es) * 1996-10-04 2003-06-16 Kyorin Seiyaku Kk Derivados de pirazolopiridinopiridazinonas y procedimiento para su preparacion.
EP0972525A4 (en) * 1997-03-18 2000-11-29 Fujisawa Pharmaceutical Co PREVENTIVE AND HEALING AGENTS AGAINST HYPERPHOSPHATEMIA
WO1999012930A1 (en) 1997-09-05 1999-03-18 Glaxo Group Limited 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors
ES2273487T3 (es) * 1998-06-01 2007-05-01 Astellas Pharma Inc. Antagonistas a1 de adenosina contra la esterilidad masculina.
WO1999067239A1 (en) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compounds and medicinal uses thereof
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
PL348208A1 (en) 1998-11-03 2002-05-06 Glaxo Group Ltd Pyrazolopyridine derivatives as selective cox-2 inhibitors
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
EP1157025B1 (en) 1999-02-27 2004-03-10 Glaxo Group Limited Pyrazolopyridines
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AU2002239344A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridines
ATE300541T1 (de) * 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridinderivate
CA2435177A1 (en) * 2001-02-20 2002-08-29 Astrazeneca Ab 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
EP1366048B1 (en) * 2001-03-08 2004-08-25 SmithKline Beecham Corporation Pyrazolopyridine derivatives
EP1372642A1 (en) * 2001-03-30 2004-01-02 SmithKline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
EP1377575B1 (en) * 2001-04-10 2006-07-05 SmithKline Beecham Corporation Antiviral pyrazolopyridine compounds
ES2242028T3 (es) * 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
WO2002088121A1 (en) * 2001-04-27 2002-11-07 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
JP2005500315A (ja) * 2001-06-21 2005-01-06 スミスクライン ビーチャム コーポレーション ヘルペスウイルス感染の予防および治療用イミダゾ［１，２−ａ］ピリジン誘導体
ATE364043T1 (de) * 2001-09-07 2007-06-15 Smithkline Beecham Corp Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
US7244740B2 (en) * 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AUPR916301A0 (en) * 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ATE373000T1 (de) * 2001-12-11 2007-09-15 Smithkline Beecham Corp Pyrazolopyridin-derivate als antiherpesmittel
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
US7585875B2 (en) 2006-06-06 2009-09-08 Avigen, Inc. Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
KR100809368B1 (ko) * 2006-08-09 2008-03-05 한국과학기술원 성대파를 이용한 음색 변환 시스템
RU2394034C2 (ru) * 2007-04-26 2010-07-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН ПРОИЗВОДНЫЕ 4,6-ДИМЕТИЛ-2,3-ДИГИДРО-1Н-ПИРАЗОЛО[4,3-c]ПИРИДИН-3-ОНОВ И ЭФИРЫ 2,6-ДИМЕТИЛ-4-ФЕНИЛ-ГИДРАЗИНОНИКОТИНОВЫХ КИСЛОТ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ ДЛЯ ИХ СИНТЕЗА, ОБЛАДАЮЩИЕ АНТИДЕПРЕССАНТНОЙ И АНКСИОЛИТИЧЕСКОЙ АКТИВНОСТЬЮ
NZ588376A (en) 2008-04-15 2011-06-30 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound having antagonism against corticotropin-releasing factor (CRF) receptor
WO2010144416A1 (en) * 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
KR101552760B1 (ko) 2009-12-18 2015-09-11 미쓰비시 타나베 파마 코퍼레이션 신규 항혈소판약
AU2013251632B2 (en) 2012-04-26 2016-12-15 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
ES2625029T3 (es) 2012-04-26 2017-07-18 Bristol-Myers Squibb Company Derivados del imidazotiadiazol como inhibidores del receptor 4 activado por proteasa (Par4) para el tratamiento de la agregación de plaquetas
CA2871599A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
KR102221002B1 (ko) * 2013-05-28 2021-02-26 라퀄리아 파마 인코포레이티드 다형체
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
ES2707124T3 (es) * 2014-08-05 2019-04-02 Raqualia Pharma Inc Derivados de serina como agonistas del receptor de grelina
WO2020191056A1 (en) * 2019-03-20 2020-09-24 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
WO2022071777A1 (ko) * 2020-09-29 2022-04-07 연세대학교 산학협력단 호흡기 질환의 예방 또는 치료용 조성물 및 예방 또는 치료 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
DK275083A (da) * 1982-06-16 1983-12-17 May & Baker Ltd Fremgangsmaade til fremstilling af et pyrazolopyridinderivat
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
JPS63135381A (ja) * 1986-11-26 1988-06-07 Kyorin Pharmaceut Co Ltd 多剤耐性癌細胞に対する感受性増強剤及びその製造方法
DE3710937A1 (de) * 1987-04-01 1988-10-13 Boehringer Mannheim Gmbh Chromogene verbindungen, ihre herstellung und verwendung als enzymsubstrate
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines

Also Published As

Publication number Publication date
PT92935B (pt) 1995-12-29
FI96205C (fi) 1996-05-27
PH30968A (en) 1997-12-23
KR0159502B1 (ko) 1998-12-01
HU211684A9 (en) 1995-12-28
JPH02243689A (ja) 1990-09-27
NO176356C (no) 1995-03-22
AU628913B2 (en) 1992-09-24
DK0379979T3 (enExample) 1997-04-07
ATE150462T1 (de) 1997-04-15
EP0379979A1 (en) 1990-08-01
IE900161L (en) 1990-07-23
KR900011773A (ko) 1990-08-01
GR3023219T3 (en) 1997-07-30
FI900307A0 (fi) 1990-01-19
RU2007403C1 (ru) 1994-02-15
NO900306L (no) 1990-07-24
IL93050A (en) 1995-05-26
US4985444A (en) 1991-01-15
IL93050A0 (en) 1990-11-05
PT92935A (pt) 1990-07-31
NO900306D0 (no) 1990-01-22
DE69030206D1 (de) 1997-04-24
DE69030206T2 (de) 1997-07-10
JPH0881465A (ja) 1996-03-26
HUT53368A (en) 1990-10-28
FI96205B (fi) 1996-02-15
UA43821C2 (uk) 2002-01-15
HU900228D0 (en) 1990-03-28
JPH0794454B2 (ja) 1995-10-11
AU4869690A (en) 1990-07-26
CA2008263A1 (en) 1990-07-23
ZA90200B (en) 1990-10-31
GB8901423D0 (en) 1989-03-15
EP0379979B1 (en) 1997-03-19
CN1044656A (zh) 1990-08-15
NO176356B (no) 1994-12-12
CA2008263C (en) 2000-03-14
CN1031570C (zh) 1996-04-17

Similar Documents

Publication Publication Date Title
ES2098229T3 (es) Compuestos de pirazolopiridina y procedimientos para su preparacion.
ES2040261T3 (es) Procedimiento para preparar acidos 6-fluor-4-oxo-1,4-dihidroquinolina-3-carboxilicos sustituidos y acidos 9-fluor-3-metil-7-oxo-2,3-dihidro-7h-pirido(1,2,3-de)(1,4)benzoxazina-6-carboxilico sustituidos.
ES2164720T3 (es) Derivados de piperidina como agentes anticolinergicos.
ES2036199T3 (es) Procedimiento de obtencion de un preparado farmaceutico administrable a traves de una membrana corporal.
DE3378470D1 (en) 7-oxabicycloheptane substituted amino prostaglandin analogs
ES2051700T3 (es) Un proceso para la preparacion de un compuesto beta-lactama.
ES541372A0 (es) Un procedimiento para la preparacion de un compuesto de 2-oxindol-1-carboxamida
ES522941A0 (es) "procedimiento para la obtencion de compuestos farmacologicamente activos por aislamiento de los factores individuales del complejo antibiotico teicomicina a2".
EG19361A (en) A process for the preparation of piperidine compound having local anaesthetica and analgetic
ES526896A0 (es) Procedimiento para la preparacion de b-carbolinas
MX6160E (es) Procedimiento para la preparacion de n-(2-fenil 2-hidroxietil)-1,1-dimetil-3-(4-fenil sustituidas)propilaminas
SE8307146L (sv) 7-oxabicykloheptan-substituerade aminoprostaglandinanaloger
ES2095068T3 (es) Peroxicarbonatos polimericos y procedimiento para prepararlos.
ES535798A0 (es) Proceso para la fabricacion de compuestos de espiro-hidantoina.
ES488708A0 (es) Un procedimiento para preparar derivados de fenilpiperidina
ES2187534T3 (es) Procedimiento para la preparacion de n-metil-3-(metil-4-piperi dinil)-14-indol-5-etanosulfonamida.
ES2008109B3 (es) Procedimiento de preparacion de aminoalcoholes y de composiciones farmaceuticas que los contienen.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
ES2021515A6 (es) Procedimiento para la preparacion de compuestos derivados de isotiazolo-piridona azetidinil substituidos.
ES2046528T3 (es) Derivados heterotetraciclicos de lactamas, proceso para su preparacion y composiciones farmaceuticas a base de los mismos.
ES2063305T3 (es) Derivados de bifenilo, procedimiento para la preparacion de los mismos e intermedios para los mismos.
ES2054234T3 (es) Un procedimiento para la preparacion de derivados indol.
DE3686706D1 (de) Glaukomhemmende zusammensetzungen und verfahren zu ihrer herstellung.
ES544859A0 (es) Un procedimiento para preparar 1-imidazolilmetilestirenos
ES2053736T3 (es) Un procedimiento para la preparacion de un derivado de ergolina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 379979

Country of ref document: ES